BGM Group (BGM) vs Cue Biopharma (CUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cue Biopharma (CUE) has outperformed BGM Group (BGM) over the past year, losing 30.0% versus a loss of 96.9%. Over five years, CUE leads with a -95.3% price change compared with -98.5% for BGM. Cue Biopharma is the larger company by market cap ($121.4 million vs $115.5 million), about 1.1 times the size.
BGM Group converts more of its revenue into profit, with a net margin of -52.6% versus -96.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | CUE |
|---|---|---|
| Share price | $8.65 | $16.71 |
| Market cap | $115.51M | $121.39M |
| 1-day change | +0.70% | -10.50% |
| YTD return | -92.19% | +82.62% |
| 1-year return | -96.86% | -30.03% |
| 5-year return | -98.52% | -95.32% |
| EPS (TTM) | $-4.80 | $-29.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $37.92M | $27.47M |
| Revenue growth (YoY) | +51.09% | +195.75% |
| Net income (latest FY) | $-19.94M | $-26.60M |
| Gross margin | 16.64% | — |
| Operating margin | -33.18% | -96.67% |
| Net margin | -52.59% | -96.85% |
| 52-week high | $303.00 | $45.50 |
| 52-week low | $6.45 | $4.98 |
| Distance from 52-week high | -97.15% | -63.27% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +426.63% |
| Average volume | 6.33K | 272.41K |
| Shares outstanding | 12.69M | 7.26M |
| Employees | — | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed BGM by 66.8 percentage points over the past year.
- BGM Group is more profitable, keeping -52.6 cents of every revenue dollar as net income versus -96.9 cents for Cue Biopharma.
- Cue Biopharma grew revenue faster in its latest fiscal year (+195.75% vs +51.09%).
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
BGM vs CUE FAQ
Which is bigger, BGM Group or Cue Biopharma?
Cue Biopharma (CUE) is larger, with a market capitalization of $121.39M compared with $115.51M for BGM Group (BGM).
Which stock has performed better over the past year, BGM or CUE?
CUE returned -30.03% over the past 12 months, compared with -96.86% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and Cue Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.